BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Knight Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Knight Therapeutics's drugs run\,
  from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT02736656-10826@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Qelbree (viloxazine): Phase 3 readout est. (NCT02736656)
DESCRIPTION:Qelbree (viloxazine)\, phase 3\, Attention Deficit Hyperactivit
 y Disorder.\nStudy: Open-label Study to Evaluate Long-term Safety and Effi
 cacy of SPN-812 (Viloxazine Extended-release Capsule)\nEstimated primary c
 ompletion: December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/viloxazine#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT02736656
URL:https://assetmemo.bio/drug/viloxazine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07382167-916@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Tenapanor (Ibsrela): Phase 3 readout est. (NCT07382167)
DESCRIPTION:Tenapanor (Ibsrela)\, phase 3.\nStudy: A 26-Wk Study to Assess 
 Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation 
 in Adults\nEstimated primary completion: 26 February 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/tenapanor-ibsrela#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07382167
URL:https://assetmemo.bio/drug/tenapanor-ibsrela#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05905926-916@assetmemo.bio
DTSTAMP:20261121T005004Z
DTSTART;VALUE=DATE:20310731
DTEND;VALUE=DATE:20310801
SUMMARY:Tenapanor (Ibsrela): Phase 3 readout est. (NCT05905926)
DESCRIPTION:Tenapanor (Ibsrela)\, phase 3\, Irritable Bowel Syndrome with C
 onstipation.\nStudy: Safety Study of Tenapanor for the Treatment of Pediat
 ric Patients (6 to Less Than 18 Years Old) With IBS-C\nEstimated primary c
 ompletion: July 2031. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /tenapanor-ibsrela#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05905926
URL:https://assetmemo.bio/drug/tenapanor-ibsrela#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
